Dr Adam Croft BSc (Hons), MBChB, PhD, MRCP (UK)

Institute of Inflammation and Ageing
NIHR Academic Clinical Lecturer in Rheumatology

Contact details

Address
Rheumatology Research Group
Institute of Inflammation and Ageing (IIA)
University of Birmingham
Queen Elizabeth Hospital, Birmingham, B15 2WB

Adam is an NIHR Academic Clinical Lecturer in Rheumatology and an honorary Specialist Registrar in Rheumatology at Sandwell and West Birmingham Hospitals and University Hospital of Birmingham NHS Trusts.

His main research interest is the development of novel immunotherapies for patients with autoimmune rheumatic and chronic inflammatory diseases, with a particular interest in the development of stromal cell (fibroblast) specific targets. He has received funding from the Wellcome Trust and NIHR.

His clinical interests include management of both early and treatment resistant inflammatory arthritis.

Qualifications

PG Cert Medical education 2018
PG Cert in Clinical Research Methodology 2015
MRCP (UK) 2012
MBChB 2009
PhD 2005
BSc (Hons) 2002

Biography

Adam obtained his first degree in Biomedical Sciences from the University of Durham where he graduated with first class honours in 2002. He subsequently undertook doctoral studies in the laboratory of Professor Stefan Przyborski (University of Durham) supported by a BBSRC CASE studentship award to examine the developmental potential of Mesenchymal Stem cells. This led to the award of a PhD in Stem Cell Biology and Regenerative Medicine in 2005. Subsequent to his research he trained in Clinical Medicine qualifying from the University of Birmingham Medical School in 2009. He was then appointed to the academic integrated clinical training programme at the University of Birmingham and during this time he worked with Professors Lorraine Harper and Chris Buckley examining the role of tissue resident stromal cells in inflammation and fibrosis.

In 2011 he was awarded an NIHR Academic Clinical Fellowship in Rheumatology and joined the Rheumatology Research Group (Professor Chris Buckley’s lab) where he continued to examine the role of specific stromal cell subsets in chronic inflammation, this time with a particular focus on the synovium. He completed postgraduate training in General Internal Medicine at University Hospital Birmingham NHS trust and was awarded Membership of the Royal College of Physicians in 2012. He was then appointed to higher speciality training in Clinical Rheumatology within the West Midlands Region and in 2014, Adam was awarded a Wellcome Trust Clinical Career Development Fellowship and in 2018 was appointed an NIHR Academic Clinical Lecturer in Rheumatology.

He undertakes a programme of research aimed at understanding the pathogenesis of inflammatory arthritis with a particular emphasis on the role of synovial fibroblasts in persistent disease. Currently, his research focuses on the use of next generation sequencing and single cell transcriptomics to understand the underlying cellular basis of chronic inflammatory diseases.

Google Scholar profile

ResearchGate profile

ORCID profile

Teaching

Year 2 BMedSci Immunology tutorials
GEC MBChB Immunology Tutorials

Research

Laboratory research is focused on mechanisms of immune-mediated synovial inflammation and the role of tissue resident stromal cells (synovial fibroblasts). His major research interests include the role of fibroblasts in the persistence of synovial inflammation and the interaction of these cells with specific leukocyte sub-populations during resolving versus persistent inflammation. He is interested in the development of novel immunotherapies that target fibroblasts in patients with inflammatory arthritis.

His current research funded by the Wellcome Trust focuses on the identification of distinct pathogenic subsets of synovial fibroblasts (the specialised tissue resident stromal cells of the synovium), using next generation sequencing platforms and single cell transcriptomics to map underlying cellular basis of inflammatory diseases.

Other activities

2018- Member of Paediatric and adolescent rheumatology network
2018- Member of Scientific Advisory Committee, NIHR Wellcome Trust Clinical Research facility, University of Birmingham
2016- UK country liaison to EMUNET EULAR advisory group (by competitive national appointment)
2016- Member of West Midlands regional vasculitis network

Previous

2015-2018 Chair of British Rheumatologists in Training Advisory Group and West Midlands regional representative (by competitive national appointment)

-          Member of British Society of Rheumatology Council

-          Member of Joint Specialty Committee at Royal College of Physicians

-          Member of rheumatology JRCTPB speciality advisory group

-          Member of Education and training subcommittee

2016-2018 Member of Clinical Care Quality committee, British Society of Rheumatology (trainee representative)

2016-2018 Member of Peer Review working group, British Society of Rheumatology (trainee representative)

2013-2017 Royal college of Physicians Associate Clinical Tutor, Queen Elizabeth Hospital, Birmingham

2012-2014 Associate Clinical Teaching Fellow, Queen Elizabeth Hospital, Birmingham

2009-2013 Advanced Life Support Instructor, Resuscitation Council UK     

Publications

1. Pathologically distinct fibroblast subsets drive inflammation and tissue damage in arthritis. Adam P Croft*, Joana Campos, Kathrin Jansen, Jason Turner, Jennifer Marshall, Musta Attar, Loriane Savary, Harris Perlman, Francesca Barone, Helen McGettrick, Douglas Fearon, Kevin Wei, Soumya Raychaudhuri, Ilya Lorsunsky, Michael Brenner, Mark Coles, Stephen Sansom, Andrew Filer, Christopher D Buckley. Nature Accepted.

2. Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis. Bustamante MF, Oliveira PG, Garcia-Carbonell R, Croft AP*, Smith JM, Serrano RL, Sanchez-Lopez E, Liu X, Kisseleva T, Hay N, Buckley CD, Firestein GS, Murphy AN, Miyamoto S, Guma M. Ann Rheum Dis. 2018;77(11):1636-1643.

3. Beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis. Hardy RS, Fenton C, Croft AP*, Naylor AJ, Begum R, Desanti G, Buckley CD, Lavery G, Cooper MS, Raza K. J. 11. Autoimmun. 2018;92:104- 113.

4. Building the future of rheumatology: the role of national and international networks. Jani M, Nikiphorou E, Croft AP*, Bukhari M. Rheumatology (Oxford) 2018:1;57(3):405-407.

5. Rheumatoid synovial fibroblasts differentiate into distinct subsets in the presence of cytokines and cartilage. Croft AP*, Naylor AJ, Marshall JL, Hardie DL, Zimmermann B, Turner J, Desanti G, Adams H, Yemm AI, Müller-Ladner U, Dayer JM, Neumann E, Filer A, Buckley CD. Arthritis Research and Therapy. 2016:18(1):270

6. Reply to: ’Giant cell or Temporal arteritis’ Croft AP, Jobanputra P. J R Coll Physicians Edinb. 2016:46(1):68-70.

7. Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis. Bartis D, Crowley LE, D'Souza VK, Borthwick L, Fisher AJ, Croft AP, Pongrácz JE, Thompson R, Langman G, Buckley CD, Thickett DR. BMC Pulm Med. 2016:14;16(1):51.

8. Cranial ultrasound for the diagnosis of giant cell arteritis. A retrospective cohort study. Croft AP, Thompson N, Duddy MJ, Barton C, Khattak F, Mollan SP, Jobanputra P. J R Coll Physicians Edinb. 2015:45(4):268-72.

9. Genetic Deletion of the Stromal Cell Marker CD248 (Endosialin) Protects against the Development of Renal Fibrosis. Smith SW, Croft AP, Morris HL, Naylor AJ, Huso DL, Isacke CM, Savage CO, Buckley CD. Nephron. 2015:131(4):265-77.

10. CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism. Wilhelm A, Aldridge V, Haldar D, Naylor AJ, Weston CJ, Hedegaard D, Garg A, Fear J, Reynolds GM, Croft AP, Henderson NC, Buckley CD, Newsome PN. Gut. 2016:65(7):1175-85.

11. Acquired haemophilia A: the importance of early recognition in cases of spontaneous bleeding in the elderly. Patel N, Wyrko Z, Naqvi S, Croft AP. BMJ Case Rep. 2014:20;2014.

12. A differential role for CD248 (Endosialin) in PDGF-mediated skeletal muscle angiogenesis. Naylor AJ, McGettrick HM, Maynard WD, May P, Barone F, Croft AP, Egginton S, Buckley CD. PLoS One. 2014:22;9(9):e107146.

13. Successful outcomes of pregnancy in patients with ANCA vasculitis. Croft AP, S.W. Smith, S. Carr, S. Youssouf, A. Salama, C. Pusey, L. Harper, M. Morgan Kidney International. 2015:87(4):807-11.

14. A very unusual headache. Croft AP, Kurdow N and Arulanantham N. Clinical Medicine 2014;14(1):58-60.

15. The MSC marker CD248 (Endosialin) is a negative regulator of bone formation. Naylor AJ, Azzam E, Smith S, Croft A, Poyser C, Duffield JS, Huso DL, Gay S, Ospelt C, Cooper MS, Isacke C, Goodyear S, Rogers MJ, Buckley CD. Arthritis and Rheumatism. 2012:64(10):3334-43

16. Paradoxical coronary artery embolism causing acute myocardial infarction in a young woman with factor V Leiden thrombophillia. Croft AP, Khan JN, Chittari MV, Varma C. J R Coll Physicians Edinb. 2012:42(3):218-20.

17. Survey of Undergraduate Rheumatology Teaching Practice in the Outpatient Clinic: Views of Patients, Medical Students and Clinicians. Croft A, Carruthers D, Justice E. Medical Teacher. 2012:34(8):674.

18. Refractory multisystem sarcoidosis responding to infliximab therapy. Adam P Croft, Deva Situnayake, Omer Khair, Gavin Giovanni and Caroline Gordon. Clinical Rheumatology. 2012:31(6):1013-8

19. CD248+ stromal cells are associated with progressive chronic kidney disease. Smith SW, Eardley KS, Croft AP, Nwosu J, Howie AJ, Cockwell P, Isacke CM, Buckley CD, Savage CO. Kidney International. 2011:80(2):199-207.

20. The Risk of Thyroid Carcinoma in Survivors of Childhood Malignant Disease – a Population Based Cohort Study: Results From the British Childhood Cancer Survivor Study. Taylor, A.J., Croft A.P., Palace A.M., Winter DL, Reulen RC, Stiller CA, Stevens MC and Hawkins, M.M. International J. Cancer. 2009:15;125(10):2400-5. 

21. Mesenchymal stem cells expressing neural antigens instruct a neurogenic cell fate decision on neural stem cells. Croft A.P. and Przyborski S.A. Experimental Neurology 2008:216(2):329-41.

22. Nimodipine prior to alcohol withdrawal prevents memory deficits during the abstinence phase. Brooks, S.P., Croft, A.P., G. Norman, S.G. Shaw and Little, H.J. Neuroscience. 2008:19;157(2):326-84.

23. Selective increases in regional brain glucocorticoid; a novel effect of chronic alcohol. Little, H.J., Croft, A.P. O'Callaghan, M.J., Brooks, S.P., Wang G and Shaw S.G. Neuroscience. 2008:28;156(4):1017-27.

24. Effects of minor laboratory procedures, adrenalectomy, social defeat or acute alcohol on regional brain concentrations of corticosterone. Croft, A.P., O'Callaghan, M.J., Connolly, G., Jacquot, C. and Little, H.J. Brain Research. 2008:31;1238:12-22.

25. Effects of the glucocorticoid antagonist, mifepristone, on the consequences of withdrawal from long term alcohol consumption. Jacquot, C., Croft, A.P., Prendergast, M.A., Mulholland, P., S.G. Shaw and Little, H.J. Alcoholism: Clinical and Experimental Research. 2008:32(12):2107-16.

26. Formation of neurons by non-neural adult stem cells: potential mechanism implicates an artifact of growth in culture. Croft A.P. and Przyborski S.A. Stem Cells. 2006:24(8):1841-51.

27. The hypothalamopituitary-adrenal axis and alcohol preference. O'Callaghan, M. J., Croft, A.P., Jacquot C, and Little, H.J. Brain Research Bulletin. 2005:30;68(3):171-8.

28. A CCKB antagonist decreased effects of social defeat on alcohol consumption. Croft A.P., Brooks S.P., Cole J. and Little, H.J. Psychopharmacology. 2005:183(2):163-70.

29. Generation of neuroprogenitor-like cells from adult mammalian bone marrow stromal cells in vitro. Croft A.P. and Przyborski S.A. Stem Cells and Development. 200413(4):409-20.

30. Effects of corticosterone on place conditioning to ethanol. Brooks S.P., Hennebry G, Croft A.P., Thomas A, Little H.J. Pyschopharmacology 2004:174(2):291-290.

31. Low alcohol preference among the 'high alcohol preference' C57 strain of mice; studies on the factors affecting preference. O'Callaghan, M.J., Croft, A.P., Watson, W.P., Brooks S.P., and Little, H.J. Pharmacology Biochemistry and Behaviour. 2002:72(1-2):475-81.

32. Effects of intraperitoneal injections of saline on alcohol and sucrose consumption of C57 strain mice. O'Callaghan, M.J., Croft, A.P., and Little, H.J. Psychopharmacology. 2002:160(2):206-212

33. Alterations in mesolimbic dopamine function during the abstinence period following chronic ethanol consumption. Little, H.J., Bailey C.P., O’Callaghan, M.J. Croft, A.P. Manley, S.J. Neuropharmacology. 2001:41(8):989-999.

 

View all publications in research portal